leadf
logo-loader
NYSE-A:VNRX

VolitionRx

Receive alerts
Market:
NYSE-A
Market Cap:
$168.47 m
Price
3.17 USD
Change
0.00%
52 weeks high
6.66
52 weeks low
2.85

In brief

Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

Snapshot

Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect coronavirus (COVID-19) patients most at-risk for hospitalization or respiratory support

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Small cap growth stocks in the spotlight at Proactive’s virtual event on July 21

Joining Proactive this time out are environmental engineering company BioLargo; life sciences group VolitionRx, and digital media platform Bright Mountain Media

on 20/7/20